Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncology Drug Development Not Advanced By Non-Inferiority Trials – Pazdur

Executive Summary

Superiority trials should be favored over non-inferiority studies for oncology drug development, FDA Oncology Drug Products Division Director Richard Pazdur, MD, suggested

You may also be interested in...



Magnitude Of Effect, Not Survival, Is Key To Approval For Oncologic Nexavar

Sponsors of oncology agents should select endpoints where a drug is likely to have a "magnitude of effect" instead of focusing on survival, FDA said following its Dec. 20 approval of Bayer/Onyx' kidney cancer therapy Nexavar (sorafenib)

Magnitude Of Effect, Not Survival, Is Key To Approval For Oncologic Nexavar

Sponsors of oncology agents should select endpoints where a drug is likely to have a "magnitude of effect" instead of focusing on survival, FDA said following its Dec. 20 approval of Bayer/Onyx' kidney cancer therapy Nexavar (sorafenib)

FDA Approach To Non-Inferiority Trials For Oncologics Too Rigid, Bristol Says

FDA's approach toward non-inferiority trials for cancer drugs is "excessively rigid," especially for targeted therapies and agents that seek to demonstrate improved safety, Bristol-Myers Squibb sai

Related Content

Topics

UsernamePublicRestriction

Register

PS044436

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel